Imunon, Inc. (IMNN)
| Market Cap | 8.76M -28.2% |
| Revenue (ttm) | n/a |
| Net Income | -14.64M |
| EPS | -4.79 |
| Shares Out | 3.98M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 33,380 |
| Open | 2.140 |
| Previous Close | 2.150 |
| Day's Range | 2.140 - 2.260 |
| 52-Week Range | 2.080 - 41.217 |
| Beta | 2.03 |
| Analysts | Strong Buy |
| Price Target | 17.60 (+700.0%) |
| Earnings Date | May 12, 2026 |
About IMNN
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company’s lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial. In addition, the company develo... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for IMNN stock is "Strong Buy." The 12-month stock price target is $17.6, which is an increase of 700.00% from the latest price.
News
Imunon reports Q1 EPS (84c), consensus ($1.28)
“Enrollment in our pivotal Phase 3 OVATION 3 trial continues ahead of plan, reflecting patient interest and strong conviction among principal investigators and the broader medical community in IMNN-00...
Imunon Earnings Call Transcript: Q1 2026
Phase III OVATION 3 trial enrollment is ahead of schedule, with strong clinical data and investigator enthusiasm supporting IMNN-001's potential in ovarian cancer. Financial discipline and creative financing strategies are extending the cash runway, while positive FDA engagement and a robust R&D pipeline position the company for key milestones in 2026 and beyond.
Imunon Earnings release: Q1 2026
Imunon released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Imunon Quarterly report: Q1 2026
Imunon has published its Q1 2026 quarterly earnings report on May 12, 2026.
IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update
IMNN-001 is the First and Only frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollment i...
IMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026
LAWRENCEVILLE, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the Company w...
Imunon Proxy statement: Proxy filing
Imunon filed a proxy statement on May 4, 2026, providing details for shareholder voting and corporate governance matters.
Imunon initiated with a Buy at Maxim
Maxim initiated coverage of Imunon (IMNN) with a Buy rating and $10 price target
Imunon Earnings Call Transcript: Q4 2025
IMNN-001 immunotherapy showed a 14.7-month median overall survival benefit in Phase II, fueling rapid Phase III enrollment and strong clinical interest. Cash runway extends into late 2026, with disciplined cost management and ongoing partnership and financing efforts.
Imunon Annual report: Q4 2025
Imunon has published its Q4 2025 annual report on March 31, 2026.
Imunon Earnings release: Q4 2025
Imunon released its Q4 2025 earnings on March 31, 2026, summarizing the period's financial results.
IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study
IMNN-001 is the first frontline immunotherapy to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with advanced ovarian cancer Final Phase 2 clin...
Imunon announces final clinical data from OVATION 2 clinical trial
Imunon (IMNN) announced final clinical data from the completed Phase 2 OVATION 2 clinical trial evaluating IMNN-001 in combination with standard of care neoadjuvant and adjuvant chemotherapy. The larg...
IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer
The increase in median overall survival among women treated with IMNN-001 in the OVATION 2 trial rose from the previously reported 11.1 months to 14.7 months following final data analysis Patients tre...
IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026
LAWRENCEVILLE, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Comp...
Imunon announces reorganization to eliminate headcount for Phase 3 trial
Imunon (IMNN) announced a strategic reorganization that will eliminate headcount not essential to the Phase 3 trial and redefine the job descriptions for additional employees to reduce operating expen...
IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY
Strategic Restructuring Eliminates Expenses Not Essential to the Phase 3 Study Khursheed Anwer, Ph.D., Executive Vice President and Chief Scientific Officer, will retire after nearly 12 years at the c...
Imunon prices 1.94M shares at $3.61 in registered direct offering
IMUNON (IMNN) entered into a securities purchase agreement with a single healthcare-focused institutional investor for the purchase and sale of 1,939,114 shares of common stock, together with warrants...
IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules
LAWRENCEVILLE, N.J., Dec. 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it has ent...
Imunon CEO says ‘poised for key milestones’ as company enters 2026
CEO Stacy Lindborg said in a shareholder letter, in part, “As we close out 2025, I am excited to reflect on a year marked by significant clinical progress, robust data…
IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026
Enrollment in the Pivotal Phase 3 OVATION 3 Study Advances Company Toward Future BLA Filing New Data from MRD Study Reinforces IMNN-001's Promise as a Potential Breakthrough Immunotherapy LAWRENCEVILL...
Imunon Earnings Call Transcript: Q3 2025
OVATION three phase III trial enrollment is ahead of plan, with strong clinical momentum and robust financial discipline. Cash runway extends into mid-Q1 2026, and multiple catalysts are anticipated, including partnership progress and further trial enrollment.
Imunon Quarterly report: Q3 2025
Imunon has published its Q3 2025 quarterly earnings report on November 13, 2025.
Imunon Earnings release: Q3 2025
Imunon released its Q3 2025 earnings on November 13, 2025, summarizing the period's financial results.
Imunon reports Q3 EPS ($1.16) vs ($3.76) last year
“IMUNON (IMNN) is rapidly advancing a potential breakthrough for women with newly diagnosed advanced ovarian cancer-a disease with no meaningful frontline treatment progress in decades,” said Stacy Li...